4.5 Article

Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda

期刊

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
卷 31, 期 8, 页码 1521-1531

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-22-0100

关键词

-

资金

  1. NCI at the NIH [UM1CA222035, UM1CA229140, UM1CA221939, UM24CA221936]
  2. Population-based Research to Optimize the Screening Process (PROSPR II) consortium

向作者/读者索取更多资源

PROSPR II consortium aims to improve cancer screening processes and reduce disparities by investigating factors affecting cervical, colorectal, and lung cancer screening. They collected screening data from over 9 million racially and ethnically diverse individuals and identified variations in patient, provider, and facility characteristics across different communities.
Background: Cancer screening is a complex process involving multiple steps and levels of influence (e.g., patient, provider, facility, health care system, community, or neighborhood). We describe the design, methods, and research agenda of the Population-based Research to Optimize the Screening Process (PROSPR II) consortium. PROSPR II Research Centers (PRC), and the Coordinating Center aim to identify opportunities to improve screening processes and reduce disparities through investigation of factors affecting cervical, colorectal, and lung cancer screening in U.S. community health care settings. Methods: We collected multilevel, longitudinal cervical, colorectal, and lung cancer screening process data from clinical and administrative sources on > 9 million racially and ethnically diverse individuals across 10 heterogeneous health care systems with cohorts beginning January 1, 2010. To facilitate comparisons across organ types and highlight data breadth, we calculated frequencies of multilevel characteristics and volumes of screening and diagnostictests/procedures and abnormalities. Results: Variations in patient, provider, and facility characteristics reflected the PROSPR II health care systems and differing target populations. PRCs identified incident diagnoses of invasive cancers, in situ cancers, and precancers (invasive: 372 cervical, 24,131 colorectal, 11,205 lung; in situ: 911 colorectal, 32 lung; precancers: 13,838 cervical, 554,499 colorectal). Conclusions: PROSPR II's research agenda aims to advance: (i) conceptualization and measurement of the cancer screening process, its multilevel factors, and quality; (ii) knowledge of cancer disparities; and (iii) evaluation of the COVID-19 pandemic's initial impacts on cancer screening. We invite researchers to collaborate with PROSPR II investigators. Impact: PROSPR II is a valuable data resource for cancer screening researchers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据